Transatlantic Conference on Clinical Trial Guidelines in Peripheral Arterial Disease: clinical trial methodology. Basel PAD Clinical Trial Methodology Group

Guidelines for the clinical development of drugs in peripheral arterial disease (PAD) have been issued by the Food and Drug Administration for the United States and by the regulatory agency of the European Union for Europe. With increasing globalization, transatlantic cooperation in drug research an...

Full description

Saved in:
Bibliographic Details
Published in:Circulation 1999-10, Vol.100 (17), p.e75-e81
Main Authors: Labs, K H, Dormandy, J A, Jaeger, K A, Stuerzebecher, C S, Hiatt, W R
Format: Article
Language:English
Subjects:
Clinical Trials as Topic - methods
Clinical Trials as Topic - standards
Guidelines as Topic
Humans
Intermittent Claudication - drug therapy
Ischemia - drug therapy
Patient Selection
Peripheral Vascular Diseases - drug therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Guidelines for the clinical development of drugs in peripheral arterial disease (PAD) have been issued by the Food and Drug Administration for the United States and by the regulatory agency of the European Union for Europe. With increasing globalization, transatlantic cooperation in drug research and development is essential for the future and would be substantially facilitated by the existence of transatlantic guidelines. A conference was held in Basel, Switzerland, in November 1997 to discuss the scientific background of the existing guidelines on the basis of published evidence and the extensive knowledge of clinical investigators and experienced regulators. The meeting was attended by 52 invited experts from the United States and Europe, as well as by representatives from the 2 regulatory authorities. The main conclusions from the meeting are presented and may serve as a reference for the future development of transatlantic guidelines for the evaluation of pharmacotherapy in PAD.
ISSN:0009-7322
1524-4539